A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Zuclopenthixol
Rovalpituzumab Tesirine
The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Robatumumab
The risk or severity of adverse effects can be increased when Robatumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Milatuzumab
The risk or severity of adverse effects can be increased when Milatuzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Bimekizumab
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ozanezumab
The risk or severity of adverse effects can be increased when Ozanezumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Clazakizumab
The risk or severity of adverse effects can be increased when Clazakizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Amatuximab
The risk or severity of adverse effects can be increased when Amatuximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Rontalizumab
The risk or severity of adverse effects can be increased when Rontalizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Depatuxizumab
The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Concizumab
The risk or severity of adverse effects can be increased when Concizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Crotedumab
The risk or severity of adverse effects can be increased when Crotedumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Naptumomab Estafenatox
The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ecromeximab
The risk or severity of adverse effects can be increased when Ecromeximab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Abituzumab
The risk or severity of adverse effects can be increased when Abituzumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Sifalimumab
The risk or severity of adverse effects can be increased when Sifalimumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Demcizumab
The risk or severity of adverse effects can be increased when Demcizumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Carlumab
The risk or severity of adverse effects can be increased when Carlumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Intetumumab
The risk or severity of adverse effects can be increased when Intetumumab is combined with Trastuzumab deruxtecan.
Zuclopenthixol
Ibalizumab
The risk or severity of adverse effects can be increased when Ibalizumab is combined with Trastuzumab deruxtecan.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3